AbbVie (ABBV) announced that the RAMQ has listed QULIPTA in their formulary for the prevention of chronic migraine and episodic migraine. This will be followed by reimbursement by private plans. The INESSS previously published a positive recommendation for the public listing of QULIPTA or atogepant in the treatment of chronic migraine in adults on July 2, 2025.
Rami Fayed, Vice President and General Manager, AbbVie Canada, said: "This positive recommendation from INESSS not only validates the clinical value of our migraine medicine but also reinforces our commitment to improving access for those living with chronic migraine and supporting physicians in delivering personalized care."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.